George Charnock
Valencia, CANPI 1235292533
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,201 of the $61,024 with a category attached, or 80.6%. Novo Nordisk accounts for 94.5% of it on its own, with 15 other manufacturers making up the rest.
Across 278 payments — averaging $219.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$58K
- Zealand Pharma US, Inc.$1K
- AbbVie$367
- Dexcom, Inc.$310
- Lifescan, Inc.$267
- Mannkind Corporation$262
- plus $756 from 10 others
What the payments were for
- Speaking & faculty fees$49,20181%
- Travel & lodging$5,4819%
- Food & beverage$5,92210%
- Education$4201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 151 | $57,658 |
| Zealand Pharma US, Inc. | 42 | $1,404 |
| AbbVie | 18 | $367 |
| Dexcom, Inc. | 14 | $310 |
| Lifescan, Inc. | 16 | $267 |
| Mannkind Corporation | 9 | $262 |
| Abbott | 10 | $257 |
| Boehringer Ingelheim | 4 | $142 |
| Corcept Therapeutics | 3 | $78 |
| AstraZeneca | 4 | $71 |
| Valeritas, Inc. | 2 | $64 |
| Medtronic | 1 | $42 |
| Companion Medical, Inc. | 1 | $37 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Amgen | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.